Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 16 |
| List of Tables | 15 | 2 |
| List of Figures | 17 | 1 |
| Introduction | 18 | 1 |
| Global Markets Direct Report Coverage | 18 | 1 |
| Bone Marrow Transplant Rejection Overview | 19 | 1 |
| Therapeutics Development | 20 | 2 |
| Pipeline Products for Bone Marrow Transplant Rejection Overview | 20 | 1 |
| Pipeline Products for Bone Marrow Transplant Rejection Comparative Analysis | 21 | 1 |
| Bone Marrow Transplant Rejection Therapeutics under Development by Companies | 22 | 5 |
| Bone Marrow Transplant Rejection Therapeutics under Investigation by Universities/Institutes | 27 | 2 |
| Bone Marrow Transplant Rejection Pipeline Products Glance | 29 | 4 |
| Late Stage Products | 29 | 1 |
| Clinical Stage Products | 30 | 1 |
| Early Stage Products | 31 | 1 |
| Unknown Stage Products | 32 | 1 |
| Bone Marrow Transplant Rejection Products under Development by Companies | 33 | 6 |
| Bone Marrow Transplant Rejection Products under Investigation by Universities/Institutes | 39 | 2 |
| Bone Marrow Transplant Rejection Companies Involved in Therapeutics Development | 41 | 66 |
| AbbVie Inc | 41 | 1 |
| AbGenomics International, Inc. | 42 | 1 |
| Actelion Ltd | 43 | 1 |
| Alexion Pharmaceuticals Inc | 44 | 1 |
| Amunix Operating Inc. | 45 | 1 |
| Apceth GmbH &Co. KG | 46 | 1 |
| arGEN-X BV | 47 | 1 |
| Athersys, Inc. | 48 | 1 |
| Bellicum Pharmaceuticals, Inc. | 49 | 1 |
| Bio-Cancer Treatment International Limited | 50 | 1 |
| Biogen Inc | 51 | 1 |
| Boryung Pharmaceutical Co., Ltd. | 52 | 1 |
| Bristol-Myers Squibb Company | 53 | 1 |
| Cantex Pharmaceuticals, Inc. | 54 | 1 |
| Capricor Therapeutics, Inc. | 55 | 1 |
| Cell Source, Inc. | 56 | 1 |
| Cell2B S.A. | 57 | 1 |
| CellECT Bio, Inc. | 58 | 1 |
| Cleveland BioLabs, Inc. | 59 | 1 |
| Compugen Ltd. | 60 | 1 |
| Cynata Therapeutics Limited | 61 | 1 |
| Cytodyn Inc. | 62 | 1 |
| Dompe Farmaceutici S.p.A. | 63 | 1 |
| Dr. Falk Pharma GmbH | 64 | 1 |
| Escape Therapeutics, Inc. | 65 | 1 |
| F. Hoffmann-La Roche Ltd. | 66 | 1 |
| Fate Therapeutics, Inc. | 67 | 1 |
| Generon (Shanghai) Corporation Ltd. | 68 | 1 |
| Gilead Sciences, Inc. | 69 | 1 |
| GlaxoSmithKline Plc | 70 | 1 |
| Idera Pharmaceuticals, Inc. | 71 | 1 |
| ImmuNext, Inc. | 72 | 1 |
| Immunomedics, Inc. | 73 | 1 |
| Incyte Corporation | 74 | 1 |
| Kadmon Corporation, LLC | 75 | 1 |
| Kamada Ltd. | 76 | 1 |
| Kiadis Pharma N.V. | 77 | 1 |
| Kymab Limited | 78 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 79 | 1 |
| MacroGenics, Inc. | 80 | 1 |
| Mallinckrodt Plc | 81 | 1 |
| Medsenic | 82 | 1 |
| Mesoblast Limited | 83 | 1 |
| Millennium Pharmaceuticals Inc | 84 | 1 |
| Neopharm Ltd. | 85 | 1 |
| Nohla Therapeutics Inc. | 86 | 1 |
| Novartis AG | 87 | 1 |
| OncoImmune, Inc. | 88 | 1 |
| OSE Immunotherapeutics | 89 | 1 |
| Pharmicell Co., Ltd. | 90 | 1 |
| Pluristem Therapeutics Inc. | 91 | 1 |
| REGiMMUNE Corporation | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 93 | 1 |
| Sarepta Therapeutics, Inc. | 94 | 1 |
| Seattle Genetics, Inc. | 95 | 1 |
| Seres Therapeutics, Inc. | 96 | 1 |
| Sigmoid Pharma Limited | 97 | 1 |
| Spherium Biomed S.L. | 98 | 1 |
| Taiga Biotechnologies, Inc. | 99 | 1 |
| Takeda Pharmaceutical Company Limited | 100 | 1 |
| Targazyme, Inc. | 101 | 1 |
| Therapix Biosciences Ltd | 102 | 1 |
| Tobira Therapeutics, Inc. | 103 | 1 |
| Vault Pharma Inc. | 104 | 1 |
| Xenikos B.V. | 105 | 1 |
| ZIOPHARM Oncology, Inc. | 106 | 1 |
| Bone Marrow Transplant Rejection Therapeutics Assessment | 107 | 14 |
| Assessment by Monotherapy Products | 107 | 1 |
| Assessment by Combination Products | 108 | 1 |
| Assessment by Target | 109 | 4 |
| Assessment by Mechanism of Action | 113 | 4 |
| Assessment by Route of Administration | 117 | 2 |
| Assessment by Molecule Type | 119 | 2 |
| Drug Profiles | 121 | 286 |
| abatacept Drug Profile | 121 | 5 |
| AbGn-168H Drug Profile | 126 | 2 |
| AGS-499 Drug Profile | 128 | 1 |
| aldesleukin Drug Profile | 129 | 2 |
| Alecmestencel-L Drug Profile | 131 | 1 |
| alpha-1 proteinase inhibitor (human) Drug Profile | 132 | 5 |
| ALXN-1007 Drug Profile | 137 | 1 |
| AMX-342 Drug Profile | 138 | 1 |
| anti-thymocyte globulin (rabbit) Drug Profile | 139 | 2 |
| Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD Drug Profile | 141 | 1 |
| Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease Drug Profile | 142 | 1 |
| ARGX-115 Drug Profile | 143 | 1 |
| arsenic trioxide Drug Profile | 144 | 1 |
| ATIR-101 Drug Profile | 145 | 4 |
| BCT-200 Drug Profile | 149 | 1 |
| begelomab Drug Profile | 150 | 1 |
| Biologic to Activate IL-2 for Graft Versus Host Disease Drug Profile | 151 | 1 |
| Biologics for Graft Versus Host Disease Drug Profile | 152 | 1 |
| bortezomib Drug Profile | 153 | 8 |
| BPX-501 Drug Profile | 161 | 4 |
| BR-05001 Drug Profile | 165 | 1 |
| brentuximab vedotin Drug Profile | 166 | 24 |
| budesonide Drug Profile | 190 | 3 |
| cannabidiol Drug Profile | 193 | 1 |
| CAP-2003 Drug Profile | 194 | 1 |
| CBLB-612 Drug Profile | 195 | 2 |
| CD-24Fc Drug Profile | 197 | 1 |
| Cell Therapy for Graft Versus Host Disease Drug Profile | 198 | 1 |
| Cell Therapy for Graft-Versus Host Disease Drug Profile | 199 | 1 |
| Cellgram for Graft Versus Host Disease Drug Profile | 200 | 1 |
| Cellular Immunotherapy for Acute Graft Versus Host Disease Drug Profile | 201 | 1 |
| Cellular Immunotherapy for Autoimmune Diseases and Transplantation Drug Profile | 202 | 2 |
| Cellular Immunotherapy for Bone Marrow Transplantation Drug Profile | 204 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 205 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 206 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 207 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 208 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 209 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 210 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 211 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma Drug Profile | 212 | 1 |
| cenicriviroc mesylate Drug Profile | 213 | 7 |
| CGEN-15001 Drug Profile | 220 | 3 |
| CRCBT-080004 Drug Profile | 223 | 1 |
| CX-01 Drug Profile | 224 | 2 |
| cyclosporine CR + cyclosporine IR Drug Profile | 226 | 1 |
| CYP-001 Drug Profile | 227 | 1 |
| entospletinib Drug Profile | 228 | 2 |
| F-652 Drug Profile | 230 | 1 |
| FR-104 Drug Profile | 231 | 3 |
| Ha-7 Drug Profile | 234 | 1 |
| ibrutinib Drug Profile | 235 | 25 |
| ImmuneSafe Drug Profile | 260 | 1 |
| ImmuStem Drug Profile | 261 | 1 |
| IMO-8400 Drug Profile | 262 | 6 |
| IT-603 Drug Profile | 268 | 1 |
| IT-901 Drug Profile | 269 | 1 |
| itacitinib adipate Drug Profile | 270 | 3 |
| KD-025 Drug Profile | 273 | 4 |
| KRP-203 Drug Profile | 277 | 2 |
| KY-1005 Drug Profile | 279 | 1 |
| MAX-16H5 Drug Profile | 280 | 1 |
| MesoStem Drug Profile | 281 | 1 |
| methoxsalen Drug Profile | 282 | 2 |
| MGD-010 Drug Profile | 284 | 2 |
| milatuzumab Drug Profile | 286 | 3 |
| Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases Drug Profile | 289 | 2 |
| MPC-CBE Drug Profile | 291 | 2 |
| natalizumab Drug Profile | 293 | 5 |
| obinutuzumab Drug Profile | 298 | 7 |
| OCU-300 Drug Profile | 305 | 1 |
| Oligonucleotide to Inhibit NFAT1 for GVHD Drug Profile | 306 | 1 |
| panobinostat Drug Profile | 307 | 8 |
| PF-05285401 Drug Profile | 315 | 11 |
| PLXR-18 Drug Profile | 326 | 7 |
| ponesimod Drug Profile | 333 | 3 |
| Preimplantation Factor Drug Profile | 336 | 1 |
| PRO-140 Drug Profile | 337 | 8 |
| ProTmune Drug Profile | 345 | 2 |
| R-348 Drug Profile | 347 | 2 |
| Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders Drug Profile | 349 | 1 |
| Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis Drug Profile | 350 | 1 |
| Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease Drug Profile | 351 | 1 |
| remestemcel-L Drug Profile | 352 | 5 |
| reparixin Drug Profile | 357 | 3 |
| RGI-2001 Drug Profile | 360 | 2 |
| RO-2959 Drug Profile | 362 | 1 |
| rovalpituzumab tesirine Drug Profile | 363 | 2 |
| ruxolitinib phosphate Drug Profile | 365 | 13 |
| S-Graft Drug Profile | 378 | 1 |
| SER-155 Drug Profile | 379 | 1 |
| Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Drug Profile | 380 | 1 |
| Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis Drug Profile | 381 | 1 |
| Small Molecules to Inhibit Perforin for Bone Marrow Transplantation Drug Profile | 382 | 1 |
| Small Molecules to Inhibit SHIP1 for Oncology and Immunology Drug Profile | 383 | 1 |
| Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders Drug Profile | 384 | 1 |
| sonidegib phosphate Drug Profile | 385 | 5 |
| SP-12008 Drug Profile | 390 | 1 |
| SYGN-305 Drug Profile | 391 | 1 |
| Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease Drug Profile | 392 | 1 |
| T-Guard Drug Profile | 393 | 2 |
| TBX-1400 Drug Profile | 395 | 1 |
| TM-5509 Drug Profile | 396 | 1 |
| TZ-101 Drug Profile | 397 | 3 |
| vedolizumab Drug Profile | 400 | 5 |
| VPI-101 Drug Profile | 405 | 1 |
| ZL-1101 Drug Profile | 406 | 1 |
| Bone Marrow Transplant Rejection Dormant Projects | 407 | 6 |
| Bone Marrow Transplant Rejection Discontinued Products | 413 | 1 |
| Bone Marrow Transplant Rejection Product Development Milestones | 414 | 12 |
| Featured News &Press Releases | 414 | 1 |
| Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease | 414 | 1 |
| Jun 21, 2016: Cynata Prepares for Phase 1 Clinical Trial | 414 | 1 |
| Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association | 415 | 1 |
| Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers | 415 | 1 |
| May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform | 416 | 1 |
| May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress | 417 | 1 |
| May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting | 418 | 1 |
| Apr 07, 2016: Cynata Reports Compelling Results from Pre-clinical Stem Cell Study in Graft-versus-Host Disease (GvHD) | 419 | 1 |
| Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 | 419 | 2 |
| Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101 | 421 | 1 |
| Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease | 421 | 1 |
| Mar 01, 2016: Top-line data from all patients on the primary endpoint of Kiadis Pharma s Phase II trial with ATIR101 selected for oral presentation at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation | 422 | 1 |
| Feb 24, 2016: First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee | 423 | 1 |
| Feb 22, 2016: Mesoblast s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease | 424 | 1 |
| Feb 16, 2016: Launch of TEMCELL HS Inj, World s First Mesenchymal Stem Cell Product for GVHD Treatment, and Commencement of Operation of Ultra-Low Cold Chain System | 425 | 1 |
| Appendix | 426 | 2 |
| Methodology | 426 | 1 |
| Coverage | 426 | 1 |
| Secondary Research | 426 | 1 |
| Primary Research | 426 | 1 |
| Expert Panel Validation | 426 | 1 |
| Contact Us | 426 | 1 |
| Disclaimer | 427 | 1 |